Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio. I rate RYTM a BUY, driven by expected double-digit revenue growth, a broader targeted-obesity portfolio, and stronger-than-expected patient uptake.
Anorexigenic neurons activate POMC, which PCSK1 cleaves into peptides including α-MSH. α-MSH activates MC4R to suppress appetite and increase satiety and energy expenditure. Diseases such as Bardet-Biedl syndrome and POMC/LEPR deficiency impair MC4R activation by reducing α-MSH production, causing severe hyperphagia (feelings of extreme hunger). IMCIVREE addresses this by reducing hyperphagia and increasing energy.
Q2 2026 Results:
Management reported strong early AHO uptake for IMCIVREE, with 400+ start forms from 300 prescribers, ahead of model assumptions. Broad prescribing suggests adoption beyond specialty centers, while international patient growth exceeded 20%. Japan AHO approval is expected before year-end, adding 6,000–8,000 addressable patients.
M&A Potential:
Rare-disease/obesity-adjacent M&A has been active and richly priced: Crinetics Pharmaceuticals' endocrine pipeline was valued at a reported $10bn, and Soleno Therapeutics (a direct PWS competitor) was acquired for approximately $2.9bn. These transactions suggest strategic and financial buyers are willing to pay substantial premiums for de-risked rare endocrine/obesity assets — a dynamic that could support multiples above our SOTP assumptions if RYTM itself became a takeout candidate. Consequently, it is our view that M&A potential increases as management further executes its clinical program.
Have other thoughts on Rhythm Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
The user peter_4mgsy holds no position in NasdaqGM:RYTM. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
